Telmisartan
Telmisartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for telmisartan tablets (a generic product), lists two uses: treating high blood pressure, and reducing the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 or older at high risk who are unable to take ACE inhibitors. The label read is a generic product label; the brand names for this substance are recorded as aliases.
Also called Micardis
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 73494; UNII U5SYW473RQ. UNII U5SYW473RQ is the UNII of the substance as the label names it. MeSH descriptor D000077333 is Telmisartan. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Ascend Laboratories, LLC label for telmisartan tablets, application ANDA205150, effective 2025-03-29 in openFDA; Drugs@FDA lists the application's sponsor as ADAPTIS. The brand label for Micardis (listed as discontinued in Drugs@FDA), other generic telmisartan labels and the combination labels were not used. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 11 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 11
- Phase 3 or 4
- 9
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Not yet recruiting | Completed | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 0 | 2 | 0 | 2 |
| Phase 3 | 0 | 4 | 0 | 4 |
| Phase 4 | 1 | 2 | 2 | 5 |
| All phases | 1 | 8 | 2 | 11 |
Conditions these trials study
- Hypertension (high blood pressure)
- Dyslipidemia
- High cholesterol (hypercholesterolemia)
- Metabolic syndrome
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context Patients for whom the US label of telmisartan tablets lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk who are unable to take ACE inhibitors
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The risk reduction indication names patients 55 years of age or older at high risk who are unable to take ACE inhibitors; the hypertension indication does not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- 55 years or older for the risk reduction indication, as the passage read states; not stated for hypertension
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with hypertension
- Patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors
- Excluded
- None stated
The US label of telmisartan tablets, USP, in the Ascend Laboratories, LLC version dated 2025-03-29 in openFDA (a generic product), lists the medicine for the treatment of hypertension, to lower blood pressure; and for reduction of the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.
Applies to Recipient not specified Patients for whom the US label of telmisartan tablets lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk who are unable to take ACE inhibitors
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-03-29
- Source state
- Current
- Version fingerprint
13ec09d12943dd0899ef011d1e41530a3b174ce48e3dbf6df4fab4d2d936f9ee- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[1], 1.2 Cardiovascular Risk Reduction
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-03-29
- Source state
- Current
- Version fingerprint
13ec09d12943dd0899ef011d1e41530a3b174ce48e3dbf6df4fab4d2d936f9ee- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250329.
- Retrieved
- Source effective date
- 2025-03-29
- Source state
- Current
- Version fingerprint
13ec09d12943dd0899ef011d1e41530a3b174ce48e3dbf6df4fab4d2d936f9ee- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].products[0].brand_name
- How it applies
- Drugs@FDA product listing for application ANDA205150, which confirms the product the label belongs to.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
b4e8cbf33dbae999da26c62354a47273feb6e44843edb33850370266ed19bb56- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
MICARDIS
No label from the application holder was found in the openFDA label dataset for application NDA020850. This page does not show another labeler's label in its place.
MICARDIS HCT
No label from the application holder was found in the openFDA label dataset for application NDA021162. This page does not show another labeler's label in its place.
TWYNSTA
No label from the application holder was found in the openFDA label dataset for application NDA022401. This page does not show another labeler's label in its place.
WIDAPLIK
No label from the application holder was found in the openFDA label dataset for application NDA219423. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified Patients for whom the US label of telmisartan tablets lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk who are unable to take ACE inhibitors
The US label of telmisartan tablets, USP, in the Ascend Laboratories, LLC version dated 2025-03-29 in openFDA (a generic product), lists the medicine for the treatment of hypertension, to lower blood pressure; and for reduction of the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reduction of the risk of myocardial infarction, stroke or cardiovascular death in people 55 or older at high risk who are unable to take ACE inhibitors as an indication: Heart attack (myocardial infarction)
Applies to Recipient not specified Patients for whom the US label of telmisartan tablets lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk who are unable to take ACE inhibitors
The US label of telmisartan tablets, USP, in the Ascend Laboratories, LLC version dated 2025-03-29 in openFDA (a generic product), lists the medicine for the treatment of hypertension, to lower blood pressure; and for reduction of the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reduction of the risk of myocardial infarction, stroke or cardiovascular death in people 55 or older at high risk who are unable to take ACE inhibitors as an indication: Stroke
Applies to Recipient not specified Patients for whom the US label of telmisartan tablets lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk who are unable to take ACE inhibitors
The US label of telmisartan tablets, USP, in the Ascend Laboratories, LLC version dated 2025-03-29 in openFDA (a generic product), lists the medicine for the treatment of hypertension, to lower blood pressure; and for reduction of the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 4
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 11
Record details
- Record id
cardio:telmisartan- Content hash
a760ec635099a0180b5495d252d9e115c4efddd62fab90e479441b00110affec